NEW YORK--(BUSINESS WIRE)-- PAVmed Inc., a medical device company organized to conceive, develop and commercialize a diversified pipeline of innovative products addressing unmet clinical needs, today announced that it has filed a Registration Statement on Form S-1 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "Commission") for a proposed $20 million initial public offering (the "Offering"). The timing and price range of the Offering have not yet been determined.

In connection with the Offering, PAVmed Inc. has applied to list its securities on the NASDAQ Capital Market under the ticker symbols "PAVMU", "PAVM" and "PAVMW".

CRT Capital Group LLC is acting as sole book-running manager for the Offering. The Offering will be made only by means of a prospectus. When available, copies of the prospectus relating to the Offering may be obtained from: Thomas B. Melly, email: tmelly@crtllc.com. A copy of the prospectus relating to the Offering may also be accessed via the Commission's website at http://www.sec.gov.

A Registration Statement relating to these securities has been filed with the Commission, but has not yet become effective. Securities may not be sold nor may offers to buy securities be accepted prior to the time the Registration Statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About PAVmed Inc.

PAVmed Inc. is a medical device company organized to conceive, develop and commercialize a diversified pipeline of innovative products to address unmet clinical needs. PAVmed’s current pipeline includes five lead projects in the areas of vascular access, tissue ablation, carpal tunnel syndrome, short term catheters and disposable infusion pumps. These projects are all in the development phase and have not yet received regulatory approval.

Cautionary Statements Concerning Forward-Looking Statements

This press release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will", variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts, product development, and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect PAVmed's business and its market, particularly those discussed in the risk factors and cautionary statements in PAVmed's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and PAVmed assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Lazar Partners Ltd.
David Carey, 212-867-1768
dcarey@lazarpartners.com

Source: PAVmed, Inc.

Released May 4, 2015